Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate powder Palbociclib
Product Description
Product Details
Product Name |
Palbociclib |
CAS No. |
571190-30-2 |
MF |
C24H29N7O2 |
MW |
447.53300 |
Appearance and shape |
Off-white or white powder |
Palbociclib is a cyclin-dependent kinase (CDK) 4 and CDK6 inhibitor approved by the FDA to treat hormone receptor-positive (HR+) human epidural 2-negative (HER2-) metastatic breast cancer. It is used in combination with letrazole as the first-line hormonal-based therapy in postmenopausal women, or with fu lvestrant in women with disease progression following hormonal therapy. Palbociclib was discovered at Warner- Lambert and developed by Pfizer after their merger. Pfizer is also studying the effectiveness of palbociclib in a variety of other cancers at various stages in the clinic.
Application & Function
Palbociclib (codenamed PD-0332991) is a drug for the treatment of ER-positive and HER2-negative breast cancer developed. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Specification
![Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate Powder Palbociclib](//www.micstatic.com/athena/img/transparent.png)
![Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate Powder Palbociclib](//www.micstatic.com/athena/img/transparent.png)
![Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate Powder Palbociclib](//www.micstatic.com/athena/img/transparent.png)
![Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate Powder Palbociclib](//www.micstatic.com/athena/img/transparent.png)
![Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate Powder Palbociclib](//www.micstatic.com/athena/img/transparent.png)
![Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate Powder Palbociclib](//www.micstatic.com/athena/img/transparent.png)